Onsdag 15 Januari | 11:22:00 Europe / Stockholm

Kalender

Tid*
2025-10-28 11:00 Kvartalsrapport 2025-Q3
2025-07-18 11:00 Kvartalsrapport 2025-Q2
2025-04-23 11:00 Kvartalsrapport 2025-Q1
2025-04-03 N/A Årsstämma
2025-02-25 12:30 Bokslutskommuniké 2024
2024-10-29 - Kvartalsrapport 2024-Q3
2024-10-15 - X-dag halvårsutdelning ORNAV 0.81
2024-10-15 - X-dag halvårsutdelning ORNBV 0.81
2024-08-08 - Kvartalsrapport 2024-Q2
2024-04-25 - Kvartalsrapport 2024-Q1
2024-03-21 - X-dag halvårsutdelning ORNAV 0.81
2024-03-21 - X-dag halvårsutdelning ORNBV 0.81
2024-03-20 - Årsstämma
2024-02-13 - Bokslutskommuniké 2023
2023-10-26 - Kvartalsrapport 2023-Q3
2023-07-17 - Kvartalsrapport 2023-Q2
2023-04-27 - Kvartalsrapport 2023-Q1
2023-03-23 - X-dag ordinarie utdelning ORNAV 1.60 EUR
2023-03-23 - X-dag ordinarie utdelning ORNBV 1.60 EUR
2023-03-22 - Årsstämma
2023-02-09 - Bokslutskommuniké 2022
2022-10-20 - Kvartalsrapport 2022-Q3
2022-07-15 - Kvartalsrapport 2022-Q2
2022-04-28 - Kvartalsrapport 2022-Q1
2022-03-24 - X-dag ordinarie utdelning ORNAV 1.50 EUR
2022-03-24 - X-dag ordinarie utdelning ORNBV 1.50 EUR
2022-03-23 - Årsstämma
2022-02-10 - Bokslutskommuniké 2021
2021-10-20 - Kvartalsrapport 2021-Q3
2021-07-19 - Kvartalsrapport 2021-Q2
2021-04-27 - Kvartalsrapport 2021-Q1
2021-03-26 - X-dag ordinarie utdelning ORNAV 1.50 EUR
2021-03-26 - X-dag ordinarie utdelning ORNBV 1.50 EUR
2021-03-25 - Årsstämma
2021-02-09 - Bokslutskommuniké 2020
2020-10-21 - Kvartalsrapport 2020-Q3
2020-07-17 - Kvartalsrapport 2020-Q2
2020-05-07 - X-dag ordinarie utdelning ORNAV 1.50 EUR
2020-05-07 - X-dag ordinarie utdelning ORNBV 1.50 EUR
2020-05-06 - Årsstämma
2020-04-28 - Kvartalsrapport 2020-Q1
2020-03-26 - X-dag ordinarie utdelning ORNBV 1.50 EUR
2020-02-05 - Bokslutskommuniké 2019
2019-10-23 - Kvartalsrapport 2019-Q3
2019-07-17 - Kvartalsrapport 2019-Q2
2019-04-25 - Kvartalsrapport 2019-Q1
2019-03-27 - X-dag ordinarie utdelning ORNAV 1.50 EUR
2019-03-27 - X-dag ordinarie utdelning ORNBV 1.50 EUR
2019-03-26 - Årsstämma
2019-02-06 - Bokslutskommuniké 2018
2018-10-24 - Kvartalsrapport 2018-Q3
2018-07-18 - Kvartalsrapport 2018-Q2
2018-04-24 - Kvartalsrapport 2018-Q1
2018-03-21 - X-dag ordinarie utdelning ORNAV 1.45 EUR
2018-03-21 - X-dag ordinarie utdelning ORNBV 1.45 EUR
2018-03-20 - Årsstämma
2018-02-07 - Bokslutskommuniké 2017
2017-10-26 - Kvartalsrapport 2017-Q3
2017-07-19 - Kvartalsrapport 2017-Q2
2017-05-18 - Kapitalmarknadsdag 2017
2017-04-26 - Kvartalsrapport 2017-Q1
2017-03-23 - X-dag ordinarie utdelning ORNAV 1.35 EUR
2017-03-23 - X-dag bonusutdelning ORNAV 0.2
2017-03-23 - X-dag ordinarie utdelning ORNBV 1.35 EUR
2017-03-23 - X-dag bonusutdelning ORNBV 0.2
2017-03-22 - Årsstämma
2017-02-08 - Bokslutskommuniké 2016
2016-10-25 - Kvartalsrapport 2016-Q3
2016-07-19 - Kvartalsrapport 2016-Q2
2016-04-27 - Kvartalsrapport 2016-Q1
2016-03-23 - X-dag ordinarie utdelning ORNAV 1.30 EUR
2016-03-23 - X-dag ordinarie utdelning ORNBV 1.30 EUR
2016-03-22 - Årsstämma
2016-02-02 - Bokslutskommuniké 2015
2015-10-27 - Kvartalsrapport 2015-Q3
2015-07-28 - Kvartalsrapport 2015-Q2
2015-05-26 - Kapitalmarknadsdag 2015
2015-04-29 - Kvartalsrapport 2015-Q1
2015-03-25 - X-dag ordinarie utdelning ORNAV 1.30 EUR
2015-03-25 - X-dag ordinarie utdelning ORNBV 1.30 EUR
2015-03-24 - Årsstämma
2015-02-04 - Bokslutskommuniké 2014
2014-10-21 - Kvartalsrapport 2014-Q3
2014-07-29 - Kvartalsrapport 2014-Q2
2014-04-29 - Kvartalsrapport 2014-Q1
2014-03-26 - X-dag ordinarie utdelning ORNAV 1.25 EUR
2014-03-26 - X-dag ordinarie utdelning ORNBV 1.25 EUR
2014-03-25 - Årsstämma
2014-02-04 - Bokslutskommuniké 2013
2013-10-22 - Kvartalsrapport 2013-Q3
2013-07-30 - Kvartalsrapport 2013-Q2
2013-04-23 - Kvartalsrapport 2013-Q1
2013-03-20 - X-dag ordinarie utdelning ORNAV 1.30 EUR
2013-03-20 - X-dag ordinarie utdelning ORNBV 1.30 EUR
2013-03-19 - Årsstämma
2013-02-05 - Bokslutskommuniké 2012
2012-10-23 - Kvartalsrapport 2012-Q3
2012-07-31 - Kvartalsrapport 2012-Q2
2012-05-24 - Kapitalmarknadsdag 2012
2012-04-24 - Kvartalsrapport 2012-Q1
2012-03-21 - X-dag ordinarie utdelning ORNAV 1.30 EUR
2012-03-21 - X-dag bonusutdelning ORNAV 0.12
2012-03-21 - X-dag ordinarie utdelning ORNBV 1.30 EUR
2012-03-21 - X-dag bonusutdelning ORNBV 0.12
2012-03-20 - Årsstämma
2012-02-07 - Bokslutskommuniké 2011
2011-10-25 - Kvartalsrapport 2011-Q3
2011-08-02 - Kvartalsrapport 2011-Q2
2011-04-27 - Kvartalsrapport 2011-Q1
2011-04-01 - X-dag ordinarie utdelning ORNAV 1.20 EUR
2011-04-01 - X-dag bonusutdelning ORNAV 0.06
2011-04-01 - X-dag ordinarie utdelning ORNBV 1.20 EUR
2011-04-01 - X-dag bonusutdelning ORNBV 0.06
2011-03-31 - Årsstämma
2011-02-09 - Bokslutskommuniké 2010
2010-10-26 - Kvartalsrapport 2010-Q3
2010-08-10 - Kvartalsrapport 2010-Q2
2010-04-27 - Kvartalsrapport 2010-Q1
2010-03-25 - X-dag ordinarie utdelning ORNAV 1.00 EUR
2010-03-25 - X-dag bonusutdelning ORNAV 0.1
2010-03-25 - X-dag ordinarie utdelning ORNBV 1.00 EUR
2010-03-25 - X-dag bonusutdelning ORNBV 0.1
2009-03-24 - X-dag ordinarie utdelning ORNAV 0.95 EUR
2009-03-24 - X-dag ordinarie utdelning ORNBV 0.95 EUR
2008-03-26 - X-dag ordinarie utdelning ORNBV 1.00 EUR
2007-04-03 - X-dag ordinarie utdelning ORNAV 1.00 EUR
2007-04-03 - X-dag ordinarie utdelning ORNBV 1.00 EUR
2006-03-22 - X-dag ordinarie utdelning ORNBV 0.85 EUR
2005-03-22 - X-dag ordinarie utdelning ORNAV 0.55 EUR
2005-03-22 - X-dag ordinarie utdelning ORNBV 0.55 EUR
2004-09-15 - X-dag bonusutdelning ORNAV 2.14
2004-09-15 - X-dag bonusutdelning ORNBV 2.14
2004-03-23 - X-dag ordinarie utdelning ORNAV 1.60 EUR
2004-03-23 - X-dag ordinarie utdelning ORNBV 1.60 EUR
2003-12-12 - X-dag bonusutdelning ORNAV 1.5
2003-12-12 - X-dag bonusutdelning ORNBV 1.5
2003-03-23 - X-dag ordinarie utdelning ORNAV 0.93 EUR
2003-03-23 - X-dag ordinarie utdelning ORNBV 0.93 EUR
2002-04-16 - X-dag ordinarie utdelning ORNAV 1.10 EUR
2002-04-16 - X-dag ordinarie utdelning ORNBV 1.10 EUR
2001-03-30 - X-dag ordinarie utdelning ORNAV 1.20 EUR
2001-03-30 - X-dag ordinarie utdelning ORNBV 1.20 EUR
2000-03-31 - X-dag ordinarie utdelning ORNAV 1.18 EUR
2000-03-31 - X-dag ordinarie utdelning ORNBV 1.18 EUR
1999-07-28 - X-dag bonusutdelning ORNAV 13.46
1999-07-28 - X-dag bonusutdelning ORNBV 13.46
1999-04-09 - X-dag ordinarie utdelning ORNAV 6.50 EUR
1999-04-09 - X-dag ordinarie utdelning ORNBV 6.50 EUR
1998-04-21 - X-dag ordinarie utdelning ORNAV 7.50 EUR
1998-04-21 - X-dag ordinarie utdelning ORNBV 7.50 EUR
1997-04-22 - X-dag ordinarie utdelning ORNAV 5.00 EUR
1997-04-22 - X-dag ordinarie utdelning ORNBV 5.00 EUR
1996-04-23 - X-dag ordinarie utdelning ORNAV 4.00 EUR
1996-04-23 - X-dag ordinarie utdelning ORNBV 4.00 EUR

Beskrivning

LandFinland
ListaLarge Cap Helsinki
SektorHälsovård
IndustriLäkemedel & Handel
Orion är en koncern med verksamhet inom läkemedelsindustrin. Bolaget bedriver forskning och utveckling av humana- och veterinära läkemedel, där störst fokus innehas inom sjukdomar som drabbar nervsystemet, samt onkologi och luftvägssjukdomar. Idag återfinns bolagets produkter på global nivå, med störst närvaro inom Norden och övriga Europa. Bolagets huvudkontor ligger i Esbo, Finland.
2023-12-27 10:00:00

ORION CORPORATION
PRESS RELEASE
27 DECEMBER 2023 at 11:00 EET              
        
NEJM Evidence publishes results from Phase I/IIa CYPIDES trial with ODM-208

The NEJM Evidence has published interim data from the first part of Phase I/II CYPIDES trial evaluating the safety and efficacy of ODM-208 (or MK-5684), an investigational, oral CYP11A1 inhibitor, in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC).

Prostate cancer continues to be regulated by steroid hormones, even in castration-resistant disease. Results from the Phase I/IIa CYPIDES trial suggest that ODM-208 potently inhibits all steroid-hormone biosynthesis with observed antitumor activity in a heavily pretreated mCRPC population, especially in patients with androgen receptor gene (AR) ligand-binding-domain (LBD) mutations.

In Phase I/IIa CYPIDES, a total of 92 previously treated mCRPC patients received 5mg of ODM-208 twice a day with glucocorticoid/mineralocorticoid replacement and ongoing androgen-deprivation therapy. In phase I, 20 out of the total 47 patients had AR LBD mutation. In phase IIa, all 45 patients had AR LBD mutation. A decrease in PSA (prostate-specific antigen) levels of 50% or more occurred in 14/19 (73.7%) patients with AR LBD mutation and 2/23 (8.7%) AR-wild-type patients in phase I, and in 24/45 (53.3%) patients with AR LBD mutation in phase IIa. Median circulating testosterone levels declined from 3.0 ng/dl at baseline to undetectable levels within the first week of ODM-208 treatment in 46/53 (87%) patients. Although well tolerated by most patients, treatment-related adrenal insufficiency was the most common safety finding. Overall 17 (36.2%) of patients in Phase I and 6 (13.3%) of patients in Phase IIa experienced adrenal insufficiency requiring adjustment of hormone replacement therapy and/or additional supplementation, after which the ODM-208 treatment commonly continued.

“These results support the continued importance of hormone-based treatments and potential of ODM-208 in prostate cancer, even in heavily treated patients with advanced disease. Additional data also shows promising improvement in managing the treatment-related adrenal insufficiency. We look forward to having further data from the latter part of the study both in AR LBD positive and negative patients.”, said Professor, M.D., Ph.D. Outi Vaarala, Senior Vice President of Innovative Medicines and Research and Development at Orion.

About ODM-208

ODM-208 (or MK-5684) is an investigational oral, non-steroidal and selective inhibitor of the CYP11A1 enzyme discovered and developed by Orion for the treatment of hormone-dependent cancers, such as prostate cancer. ODM-208 is being developed through a collaboration with MSD (tradename of Merck & Co., Inc. Rahway NJ USA).                                                

Link to the article: https://evidence.nejm.org/doi/full/10.1056/EVIDoa2300171

Contact person:
Terhi Ormio, VP, Communications
Orion Corporation
tel. +358 50 966 4646

                                                    

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orion.fi

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.